These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 17149864

  • 1. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A, Reddy GS, Cao H, Anjum SG, Nalam MN, Schiffer CA, Rana TM.
    J Med Chem; 2006 Dec 14; 49(25):7342-56. PubMed ID: 17149864
    [Abstract] [Full Text] [Related]

  • 2. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK, Swanson LM, Cho H, Leshchenko S, Hussain KA, Kay S, Walters DE, Koh Y, Mitsuya H.
    J Med Chem; 2005 May 19; 48(10):3576-85. PubMed ID: 15887965
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB, Cantin LD, Pasternak A, Guise-Zawacki L, Yao W, Charnley AK, Barbosa J, Sprengeler PA, Hirschmann R, Munshi S, Olsen DB, Schleif WA, Kuo LC.
    J Med Chem; 2003 May 08; 46(10):1831-44. PubMed ID: 12723947
    [Abstract] [Full Text] [Related]

  • 4. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF, Furfine ES, Hanlon MH, Hazen RJ, Ray JA, Robinson L, Samano V, Spaltenstein A.
    Bioorg Med Chem Lett; 2004 Feb 23; 14(4):959-63. PubMed ID: 15013001
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK, Schiltz G, Perali RS, Leshchenko S, Kay S, Walters DE, Koh Y, Maeda K, Mitsuya H.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1869-73. PubMed ID: 16480871
    [Abstract] [Full Text] [Related]

  • 6. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK, Kincaid JF, Walters DE, Chen Y, Chaudhuri NC, Thompson WJ, Culberson C, Fitzgerald PM, Lee HY, McKee SP, Munson PM, Duong TT, Darke PL, Zugay JA, Schleif WA, Axel MG, Lin J, Huff JR.
    J Med Chem; 1996 Aug 16; 39(17):3278-90. PubMed ID: 8765511
    [Abstract] [Full Text] [Related]

  • 7. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
    Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM.
    J Med Chem; 2007 Sep 06; 50(18):4316-28. PubMed ID: 17696512
    [Abstract] [Full Text] [Related]

  • 8. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT.
    J Med Chem; 1997 Jan 17; 40(2):181-91. PubMed ID: 9003516
    [Abstract] [Full Text] [Related]

  • 9. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M, Zhang H, Yao X, Eckart M, Zuo E, Yang M.
    Chem Biol Drug Des; 2010 Aug 17; 76(2):174-80. PubMed ID: 20572811
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB, Charnley AK, Harada H, Beiger JJ, Cantin LD, Kenesky CS, Hirschmann R, Munshi S, Olsen DB, Stahlhut MW, Schleif WA, Kuo LC.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):859-63. PubMed ID: 16298527
    [Abstract] [Full Text] [Related]

  • 11. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL, Zhao C, Stewart KD, Betebenner DA, Lin S, Park CH, Kong XP, Rosenbrook W, Herrin T, Madigan D, Vasavanonda S, Lyons N, Molla A, Saldivar A, Marsh KC, McDonald E, Wideburg NE, Denissen JF, Robins T, Kempf DJ, Plattner JJ, Norbeck DW.
    J Med Chem; 1996 Jan 19; 39(2):392-7. PubMed ID: 8558507
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
    Gao BL, Zhang CM, Yin YZ, Tang LQ, Liu ZP.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3730-3. PubMed ID: 21555220
    [Abstract] [Full Text] [Related]

  • 13. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV, Lunney EA, Para KS, Tummino PJ, Ferguson D, Hupe D, Domagala JM, Erickson JW.
    Drug Des Discov; 1996 Apr 15; 13(3-4):15-28. PubMed ID: 8874041
    [Abstract] [Full Text] [Related]

  • 14. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
    Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Schiffer CA, Rana TM.
    J Med Chem; 2010 Nov 11; 53(21):7699-708. PubMed ID: 20958050
    [Abstract] [Full Text] [Related]

  • 15. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S, Janakiraman MN, Chong KT, Tomich PK, Dolak LA, Turner SR, Strohbach JW, Lynn JC, Horng MM, Hinshaw RR, Watenpaugh KD.
    J Med Chem; 1996 Jun 07; 39(12):2400-10. PubMed ID: 8691434
    [Abstract] [Full Text] [Related]

  • 16. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J, Sabnis YA, Vrang L, Samuelsson B, Karlén A, Hallberg A, Larhed M.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5303-15. PubMed ID: 16621572
    [Abstract] [Full Text] [Related]

  • 17. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q, Chang CH, Li R, Ru Y, Jadhav PK, Lam PY.
    J Med Chem; 1998 Jun 04; 41(12):2019-28. PubMed ID: 9622543
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC, Robbins A, Graña P, Paleo MR, Correa JF, Villaverde MC, Sardina FJ, Govindasamy L, Agbandje-McKenna M, McKenna R, Dunn BM, Sussman F.
    J Med Chem; 2008 Feb 28; 51(4):852-60. PubMed ID: 18215016
    [Abstract] [Full Text] [Related]

  • 19. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J, Bonham NM, Nillroth U, Hansson T, Zuccarello G, Bouzide A, Aqvist J, Classon B, Danielson UH, Karlén A, Kvarnström I, Samuelsson B, Hallberg A.
    J Med Chem; 1997 Mar 14; 40(6):885-97. PubMed ID: 9083477
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
    Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, Weerasena V, Turner R, Koelsch G, Bilcer G, Tang J.
    J Med Chem; 2007 May 17; 50(10):2399-407. PubMed ID: 17432843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.